• Rama Shukla Department of Pharmaceutics, Ravishankar College of Pharmacy, By Pass Road, Bhanpur Chouraha, Bhopal 462010 (M. P) India
  • L. K. Omray Technocrats Institute of Technology-Pharmacy, Anand Nagar, Bhopal, 462021(M. P) India


Present study deals with the formulation and characterization of matrix type transdermal drug delivery system (TDS) of diltiazem hydrochloride for the treatment of hypertension. The TDS was prepared by the solvent evaporation method on a mercury substrate. Ten formulations were prepared which differed in the ratio of matrix forming polymers. Formulations TDS1 to TDS10 were composed of HPMC (hydroxypropyl methylcellulose), PVA (polyvinyl alcohol) and gelatin 10%, w/v in the combination of single polymer, two polymer (1:1) and three polymer in the ratio of 1:1:1, 1:2:1, 2:1:1 and 1:1:2 respectively. All the ten formulations contained 5 % (w/w) of diltiazem hydrochloride, 1 % (v/w) of propylene glycol and 1 % (w/w) of tween 80 (based on total polymer weight). The transdermal drug delivery system characterized for various physicochemical properties such as thickness, moisture content (MC), moisture uptake, water vapor transmission (WVT), folding endurance, drug excipients interaction, drug content and in vitro release study. On the basis physicochemical properties and in vitro release study, formulation TDS8 was found to be better than the other formulations and it was selected as the developed formulation.

Keywords: Diltiazem, Hypertension, Transdermal drug delivery, In vitro evaluation


1. Misra AN, Transdermal drug delivery. In: Jain NK. editors. Controlled and novel drug delivery. New Delhi: CBS Publishers and Distributor; 1997;1:100-29.
2. Vyas SP, Khar RK. Controlled drug delivery, concepts and advances. Delhi: Vallabh Prakashan; 2008. p. 412.
3. Kumar JA, Pullakandam N, Prabu SL. Trandermal drug delivery system: an overview. Int J Pharm Sci Rev Res 2010;3:49-53.
4. Ansel HC, Allen LV, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. Lippincott Williams and Wilkins, USA, Printed in India at Gopsons Papers Ltd. Noida; 2005;7:63-78.
5. Kerins DM, Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman JG, Limbrid LE, Goodman A. editors. A text book of pharmacological basis of therapeutics. McGraw-Hill; 2001;10:855-63.
6. Iannuccelli V, Coppi G, Bernabei MT, Cameroni R. Air compartment multiple-unit
7. System for prolonged gastric residence. Part I. Formulation study. Int J Pharm 1998;174:47-54.
8. Brijesh SD, Avani FA, Madhabhai MP. Gastrorententive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech 2004;5:77-82.
9. Aggarwal G, Dhawan S. Development, fabrication and evaluation of transdermal drug delivery system-a review.; 2009. p. 7.
10. Balasubramanyam VI, Vasavada RC. Evaluation of lanolin alcohol films and kinetics of triamcinolone acetonide release. J Pharm Sci 1979;68:782-7.
11. Kanig JL, Goodman H. Evaluative procedures for film-forming materials used in pharmaceutical applications. J Pharm Sci 1962;51:77-83.
12. Guy RH, Hadgrft J. Physicochemical aspects of percutaneous penetration and its enchancement. Pharm Res 1988;5:753-8.
13. Chien YW, Keshary PR, Hang YC, Sarpotdar PP. Comparative controlled skin permeation of nitroglycerin from marketed transdermal delivery systems. J Pharm Sci 1983;72:968-70.
14. Aqil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metaprolol tratrate: in vitro characterization. Acta Pharm 2003;53:119-26.
15. Aqil M, Ali A, Sultana Y, Dubey K, Najmi AK, Pillai KK. In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical note. AAPS PharmSciTech 2006;7:E1-E5.
198 Views | 888 Downloads
How to Cite
Shukla, R., and L. Omray. “FORMULATION AND CHARACTERIZATION OF DILTIAZEM TRANSDERMAL SYSTEM FOR THE TREATMENT OF HYPERTENSION”. International Journal of Current Pharmaceutical Research, Vol. 8, no. 3, July 2016, pp. 12-15,
Review Article(s)